Epigenetic mechanisms in non-small cell lung cancer therapy and chemoresistance
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2025
DOI: 10.1016/j.bbcan.2025.189356 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2025. Verfasst von Ying Xu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, No.37 Guoxue Alley, Chengdu 610041, Sich…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Drug Resistance, Neoplasm, Epigenesis, Genetic, Lung Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 297 Literaturangaben. Gefördert von: National Natural Science Foundation of China, West China Hospital, Sichuan University, Sichuan University.
Abstract (Originalsprache)
Epigenetic mechanisms play a crucial role in cancer development and progression, encompassing DNA methylation, chromatin organization, histone modifications, and noncoding RNA regulation. Lung cancer is a major cause of cancer-related deaths worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85 % of all cases. Despite advances in detection and treatment, the prognosis for NSCLC patients remains poor, largely attributable to the development of chemoresistance. Chemoresistance is a key driver of cancer recurrence and metastasis. Targeting epigenetic modifications emerges as a promising strategy to reverse chemoresistance. Elucidating the mechanisms by which epigenetic modulation influences chemoresistance in NSCLC, coupled with the development of drugs to counteract this phenomenon, offers significant potential to improve the survival rates and quality of life for NSCLC patients. In this review, we comprehensively summarize the contributions of various epigenetic regulators to chemoresistance in NSCLC. We also explore the relationship between distinct epigenetic modifications and chemoresistance in NSCLC and discuss the translational potential of these findings into clinical therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, No.37 Guoxue Alley, Chengdu 610041, Sichuan, China.
- Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu 610041, China.
- Uniklinik RWTH Aachen and Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, 52074 Aachen, Germany.
- Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu 610041, China. Electronic…
- Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, No.37 Guoxue Alley, Chengdu 610041, Sichuan, China. Electronic address: newzhuqing1972@scu.edu.cn.
Förderung
- National Natural Science Foundation of China
- West China Hospital, Sichuan University
- Sichuan University
- China Postdoctoral Science Foundation
Zitieren
APA
Xu, Y., Meng, Y., Xu, Y., Han, J., & Zhu, Q. (2025). Epigenetic mechanisms in non-small cell lung cancer therapy and chemoresistance. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. https://doi.org/10.1016/j.bbcan.2025.189356
Vancouver
Xu Y, Meng Y, Xu Y, Han J, Zhu Q. Epigenetic mechanisms in non-small cell lung cancer therapy and chemoresistance. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2025. doi:10.1016/j.bbcan.2025.189356
BibTeX
@article{Xu2025,
author = {Xu, Ying and Meng, Yang and Xu, Yongfeng and Han, Junhong and Zhu, Qing},
title = {Epigenetic mechanisms in non-small cell lung cancer therapy and chemoresistance},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2025},
doi = {10.1016/j.bbcan.2025.189356}
}
EUVIMED